SPRX002 + ARC-T Cells
Phase 1UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Trial Timeline
Nov 28, 2022 → Nov 17, 2025
NCT ID
NCT05457010About SPRX002 + ARC-T Cells
SPRX002 + ARC-T Cells is a phase 1 stage product being developed by Arcellx for Acute Myeloid Leukemia. The current trial status is unknown. This product is registered under clinical trial identifier NCT05457010. Target conditions include Acute Myeloid Leukemia, Myelodysplastic Syndromes.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
4
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05457010 | Phase 1 | UNKNOWN |
Competing Products
20 competing products in Acute Myeloid Leukemia